Is a test of cure necessary following treatment for cervical infection with *Chlamydia trachomatis*?

K W Radcliffe, D Rowen, D E Mercet, G Mumtaz, G L Ridgway, A J Robinson, J S Bingham

**Abstract**

Tests of cure (TOC) were performed on specimens from 106 women following treatment for chlamydial infection of the cervix. Ninety women attended for the first TOC with enzyme immunoassay (EIA) within one week of finishing antibiotics. Three were EIA positive, 88 were EIA negative. These three women were subsequently EIA and culture negative although they received no further antibiotics. Ninety women returned for the second TOC with EIA and culture between seven and 27 days after completing treatment. All the results were negative. Routine TOC is unnecessary following appropriate antimicrobial therapy. If TOC is indicated antigen-detection methods should not be used immediately after finishing antibiotics as misleading positive results may be obtained. EIA or culture at one week or later after treatment is reliable.

**Introduction**

Infection of the lower genital tract with *Chlamydia trachomatis* is one of the commonest sexually transmitted diseases. It is common clinical practice following treatment to repeat microbiological tests to ensure chlamydiae have been eradicated. This study was undertaken to investigate whether such a test of cure (TOC) is necessary and if so whether enzyme immunoassay (EIA) or cell-culture is the more appropriate test and how long after completion of treatment it should be done.

**Patients and methods**

Female patients attending the departments of Genitourinary Medicine at the Middlesex and University College Hospitals who had positive cervical cultures for *C. trachomatis* were recruited into the study. Suitable patients were identified in two ways:

1. Women attending the departments were screened for chlamydiae by EIA (Chlamydiazyme, Abbott Laboratories). Women with positive EIA had cultures taken prior to treatment;
2. Women attending as contacts of men with non-gonococcal urethritis (NGU) had cultures taken before receiving antibiotics.

Informed consent was obtained from all subjects. Treatment prescribed was either doxycycline 100 mg twice a day or oxytetracycline 500 mg four times a day, for seven days.

Subjects were advised to abstain from intercourse until cure was established. They were asked to return the day after finishing antibiotics for TOC with EIA and after a further seven days for a second TOC with EIA and culture. Women attending more than seven days after completing treatment were excluded from analysis of the first TOC.

Specimens for EIA were collected, transported and examined according to the manufacturer’s recommendations. Positive results were confirmed by a specific blocking antibody test. Specimens giving equivocal results were further examined by direct immunofluorescence (Microtrak, Syva Company) of the EIA buffer as described in a previous study.¹

Specimens for culture were obtained from the endocervical canal using cotton-wool tipped swabs after the ectocervix had been wiped with a cotton-wool ball. Specimens were transported to the laboratory in 2-sucrose phosphate medium and inoculated onto duplicate monolayers of cycloheximide-treated McCoy cells. After incubation for 48 to 72 hours one culture was fixed, stained with iodine and examined for typical inclusions. If no chlamydiae were detected the second culture was passaged onto fresh McCoy cells and after a further 48 to 72 hours incubation was examined by direct immunofluorescence (Syva Microtrak *C. trachomatis* Culture Confirmation Test).

**Results**

One hundred and six women returned for one or both TOC. Culture was positive prior to treatment in 105. One was culture-negative but positive to both EIA...
and direct immunofluorescence (DFA) and was therefore included.

Fifty six women were treated with doxycycline and 49 with oxytetracycline. One woman was pregnant and received erythromycin 500 mg twice a day for seven days.

Ninety one women attended for the first TOC. One returned one day prior to completing treatment, the rest between one and seven days after finishing therapy. EIA was negative in 88, three were EIA positive. These three women were all examined the day after finishing antibiotics and all were EIA and culture negative at their second TOC seven, eight and fourteen days later respectively, having received no further treatment. Seventy five of these women also attended for the second TOC and all were both EIA and culture negative.

A total of 90 women returned for the second TOC between seven and 27 days after treatment. All 90 were culture negative. Eighty nine were also EIA negative (EIA was omitted in one).

Discussion
In this study microbiological cure was established in all 90 women who returned for the final TOC. This is consistent with the following laboratory and clinical evidence which indicates that antichlamydial therapy is extremely effective unless there is non-compliance or the patient is reinfected.

In vitro assays show C. trachomatis to be highly susceptible to the tetracyclines and erythromycin. Naturally occurring resistance of chlamydiae to these antibiotics has never been described.

In the largest series of women followed after treatment for cervical infection with C. trachomatis, 161 women were examined repeatedly for up to 20 months after taking oxytetracycline 250 mg four times a day for 21 days. Chlamydiae were detected by culture in 16 (10%) at times between two weeks and 12 months. However, ten of these women had current partners with proven gonorrhoea, NGU or chlamydial infection, and the remaining six were all having intercourse with the original or a new partner. Therefore, reinfecion and not treatment failure was the probable explanation for the re-isolation of chlamydiae in all cases.

Erythromycin has been shown to be as effective as oxytetracycline in the treatment of cervical infection with C. trachomatis.

The results of this present study indicate that routine TOC following therapy for cervical chlamydial infection is unnecessary. This accords with the advice of both the Centers for Disease Control7 and the World Health Organisation."


Accepted for publication 17 September 1990.